India Pharma Outlook Team | Wednesday, 17 December 2025
Biocon Biologics Limited, an integrated global biopharmaceutical group and a subsidiary of Biocon Limited have been named under IAM (Intellectual Asset Management).
IAM is a leader in international intellectual property publications, to Biocon Biologics Asia IP Elite 2025 within a select few organizations within Asia creating strong IP values and leadership in this area.
The recognition was bestowed on the company at IPBC Asia in Tokyo from Nov 18 - 20, 2025. The IAM Asia IP Elite List celebrates organizations that create meaningful connections between their strategies for using intellectual property and their innovative and business performance achievements following an extensive review of both quantitative and qualitative data related to the intellectual property industry in Asia.
Also Read: How Emerging Biotech Startups Reshaping the Bioprocessing Future
Biocon was the first Indian pharmaceutical company to appear on the Asia IP Elite List in 2016 based on Biocon’s structured approach to, and forward-thinking regarding, IP Management. Biocon Biologics has maintained that emphasis on excellence in respect of IP management. For the ninth year in a row, Biocon and Biocon Biologics have been recognized by the IAM as members of their Asia IP Elite List, demonstrating Biocon and Biocon Biologics’ dedication to achieving excellence in intellectual property.
Shreehas Tambe, CEO & Managing Director, Biocon Biologics, said: “Our inclusion in the Asia IP Elite list for 2025 marks the ninth consecutive year that Biocon and Biocon Biologics have appeared on this prestigious list. This reflects our sustained commitment to innovation and strong intellectual property strategy. It reinforces our growing stature as a global biosimilars leader and the role of our IP strategy in expanding access to high-quality, affordable therapies for patients worldwide.”
Each year, the IAM editorial team conducts an extensive research process, incorporating both quantitative and qualitative analyses, to highlight an exclusive group of leading corporations and research institutions as inductees into the Asia IP Elite.
